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Abstract
Aims/hypothesis Universal screening for gestational diabetes
mellitus (GDM) has not been implemented, and this has had
substantial clinical implications. Biomarker-directed targeted
screening might be feasible. We sought to determine the ac-
curacy of circulating adiponectin for early prediction of GDM.
Methods A systematic review and meta-analysis of the litera-
ture to May 2015 identified studies in which circulating
adiponectin was measured prior to a diagnosis of GDM.
Data on diagnostic accuracy were synthesised by bivariate
mixed effects and hierarchical summary receiver operating
characteristic (HSROC) models.
Results Thirteen studies met the eligibility criteria, 11 of
which (2,865 women; 794 diagnosed with GDM) had extract-
able data. Circulating adiponectin had a pooled diagnostic
odds ratio (DOR) of 6.4 (95% CI 4.1, 9.9), a summary sensi-
tivity of 64.7% (95% CI 51.0%, 76.4%) and a specificity of
77.8% (95% CI 66.4%, 86.1%) for predicting future GDM.
The AUC of the HSROC was 0.78 (95% CI 0.74, 0.81). First
trimester adiponectin had a pooled sensitivity of 60.3% (95%
CI 46.0%, 73.1%), a specificity of 81.3% (95% CI 71.6%,
88.3%) and a DOR of 6.6 (95% CI 3.6, 12.1). The AUC
was 0.79 (95% CI 0.75, 0.82). Pooled estimates were similar
after adjustment for age, BMI or specific GDM diagnostic
threshold.
Conclusions/interpretation Pre-pregnancy and early pregnan-
cy measurement of circulating adiponectin may improve the
detection of women at high risk of developing GDM.
Prospective evaluation of the combination of adiponectin
and maternal characteristics for early identification of those
who do and do not require OGTT is warranted.
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Abbreviations
DOR Diagnostic odds ratio
GDM Gestational diabetes mellitus
HSROC Hierarchical summary receiver operating
characteristic
ROC Receiver operating characteristic
Introduction
Gestational diabetes mellitus (GDM) can affect between 1%
and 20% of pregnancies, depending on the diagnostic criteria
used or the population studied, and is associated with a range of
adverse maternal and neonatal outcomes [1–3]. Randomised
controlled trials have confirmed that, in routine antenatal care,
identification and treatment of GDM, even in its mildest form,
reduces the incidence of hypertensive disorders, Caesarean sec-
tion, macrosomia and shoulder dystocia [4, 5]. Limited re-
sources and infrastructure have, however, led to an ongoing
debate regarding the effectiveness of universal screening
Electronic supplementary material The online version of this article
(doi:10.1007/s00125-015-3855-6) contains peer-reviewed but unedited
supplementary material, which is available to authorised users.
* Stamatina Iliodromiti
stamatina.iliodromiti@glasgow.ac.uk
1 School of Medicine, Glasgow Royal Infirmary, University of
Glasgow, Level 2, New Lister Building, Glasgow G31 2ER, UK
2 Jack Cole Building, University of St Andrews, St Andrews, UK
3 Institute of Cardiovascular and Medical Sciences, University of
Glasgow, Glasgow, UK
Diabetologia (2016) 59:692–699
DOI 10.1007/s00125-015-3855-6
compared with targeted screening based on maternal baseline
characteristics [6], despite the latter identifying only around
half of affected women [7].
Improvement of targeted screening by inclusion of first
trimester biomarkers may be feasible, facilitating stratified
care and early intervention. Yet assessment of fructosamine
or HbA1c has not been shown to enhance GDM prediction,
due to the substantial overlap of values between affected and
non-affected individuals [8, 9]. A range of alternative bio-
markers have been proposed: the adipokine adiponectin (mea-
surable in the non-fasting state) is the most promising [10], as
it seems to nicely ‘capture’ insulin resistance, a precursor of
the disease, rather than measure glycaemia per se [10].
Contemporary cross-sectional studies have shown that GDM
is associated with lower levels of circulating adiponectin [11],
but the majority of studies assessing the value of serum
adiponectin as a screening tool prior to the diagnosis of
GDM are limited by their small sample size [12, 13], or re-
stricted to specific subpopulations [13–15]. To provide a more
accurate estimate of the effect size we undertook a systematic
review and meta-analysis of all eligible studies to examine
whether adiponectin can be a useful early pregnancy predictor
of future GDM.
Methods
The study was conducted according to the PRISMA guide-
lines [16], and followed a structured protocol which was
agreed among the authors in advance of the literature search.
Data sources and searches We searched several electronic
databases up to May 2015, namely, PubMed, EMBASE,
MEDLINE, Web of Science and the Cochrane Library. The
following search terms were combined using Boolean rules:
gestation*, diabetes, pregnan*, adiponec*, with a filter for
human studies without language restriction. The full search
strategy is provided in the electronic supplementary material
(ESMMethods). Two researchers (SI and JS) screened all the
titles and abstracts; studies including data on circulating
adiponectin levels and GDM were read in full. The reference
lists of the selected papers were hand-searched to identify
additional papers. Grey literature was searched via the open-
grey website.
Study selection We included studies that met the following
criteria: (1) the study population includedwomen of reproduc-
tive age without existing diabetes; (2) serum adiponectin was
measured prior (pre-pregnancy or index pregnancy) to the
diagnosis of GDM; (3) the clinical outcome was GDM diag-
nosed by OGTTagainst reference criteria (in view of the chro-
nological evolvement of the diagnostic criteria and discrepan-
cies across different countries, we did not restrict to specific
diagnostic criteria); (4) any study design, apart from case re-
ports, without a language restriction. In the meta-analysis, we
included studies if 2×2 tables could be constructed from pub-
lished or requested data.
Two researchers (SI and JS) independently assessed the
papers for final selection. If a study fulfilled the eligibility
criteria, it was included in the systematic review. Any discrep-
ancies were resolved with discussion. A third reviewer (SMN)
was consulted if any unresolved issues persisted.
Data extraction and quality assessment If a study had ex-
tractable data to construct a 2×2 table with the number of
false positives, false negatives, true positives and true nega-
tives, or the sensitivity, specificity or AUC of the receiver
operating characteristic (ROC) curve of circulating
adiponectin in the prognosis of GDM, then it was included
in the meta-analysis. If a study was selected for the systematic
review but did not provide data that could be included in the
meta-analysis, the authors were contacted via e-mail. If the
authors did not reply or did not provide the requested infor-
mation, but the relevant information was extractable using a
reverse engineering technique through Plot Digitizer
(downloaded from http://plotdigitizer.sourceforge.net/), a
computer software programme which can extract data from
published plots, the articles and data therein were used in the
meta-analysis [17–19].
We developed a data extraction Excel sheet which included
the following information: study characteristics (first author,
year of publication, number of participants with and without
diagnosed GDM), study sample characteristics (mean age,
BMI, ethnicity if applicable), test characteristics (method of
measuring serum adiponectin, mean value of adiponectin in
those with and those without GDM, threshold levels, sensitiv-
ity, specificity and AUC of ROC if available in the primary
studies) and reference standards for diagnosing GDM.
We used the QUADAS-2 checklist to assess the quality of
the selected studies and the risk of bias associated with the
study protocol [20]. We assessed the risk of publication bias
and potential small study effect visually by constructing a
funnel plot, which plots estimates of diagnostic accuracy
against statistical precision [21]. In addition, we performed a
linear regression of log diagnostic ratios on the inverse root of
effective sample sizes as a test for funnel plot asymmetry,
where a non-zero slope coefficient (p<0.10) is suggestive of
asymmetry and small study bias [22].
Data synthesis and analysis We used STATA/SE (version
12.1; StataCorp LP, College Station, TX, USA) and SAS/
STAT software (SAS Institute, Cary, NC, USA) for statistical
analysis. We used the random effects model for binary data to
estimate a summary measure of diagnostic odds ratio (DOR)
with 95% CIs. The DOR summarises the diagnostic accuracy
of a test and can take values from 0 to infinity. A DOR of 1
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represents an uninformative test; as the DOR increases it re-
flects a test with increasing discriminatory power. Herein, it
expresses the odds of having low levels of adiponectin below
a given threshold associated with GDM in each study (positive
test results) among women with GDM relative to the odds of
high adiponectin levels among women without GDM [23, 24].
Heterogeneity resulting from true diagnostic accuracy not be-
ing identical in each study was quantified by the I2 measure
[25], and visually explored by generating a forest plot for the
DOR of adiponectin with 95% CIs for each individual study.
We conducted meta-regression analysis to assess what propor-
tion of the heterogeneity is explained by the discrepancy in
specific variables (BMI, age, method ofmeasuring adiponectin,
reference criteria of diagnosing GDM, adiponectin cut-off
points, timing of measuring adiponectin and ethnicity) among
the pooled studies and sensitivity analysis to assess the impact
of differential timing in measuring adiponectin and the impact
of different participant characteristics in our pooled estimates.
We adjusted the DOR separately for age, diagnostic criteria of
GDM and BMI. In addition, we estimated a summary ROC
curve, specificity, sensitivity, and negative and positive likeli-
hood ratio of adiponectin in predicting GDM by fitting a two-
level mixed logistic regression model, with independent bino-
mial distributions for the true positive and true negative restrict-
ed to the sensitivity and specificity in each study, and a bivariate
normal model for the logit transforms of sensitivity and speci-
ficity between studies [26–28].
Ethics Ethics approval was not required, as we pooled previ-
ously published studies.
Results
Search results Figure 1 summarises the search process and
numerical selection of the final papers that were included in
the systematic review and meta-analysis. The systematic
search of the biomedical databases resulted in 1,095 hits; after
excluding duplicates, 489 citations were identified.We did not
identify any unpublished literature relevant to our topic. We
selected 39 papers based on their abstract and title, which were
read in full for eligibility. Two eligible studies referred to the
same study group; hence, only one of them was included in
the systematic review [29, 30]. Thirteen individual studies
fulfilled the eligibility criteria and were included in the sys-
tematic review [12–15, 29, 31–38], whereas 11 studies had
extractable data after contacting the authors and were included
in the meta-analysis [12–15, 29, 31, 32, 34, 36, 37].
Description of studies The characteristics of the 13 studies
included in the systematic review are listed in ESM Table 1.
The majority of the studies assessed the value of adiponectin
in the first trimester, whereas the diagnosis of GDM was
established at the end of the second trimester by an OGTT
[12–14, 31, 33–37]. Some studies sampled specific popula-
tions such as nulliparous women [31], women at high risk of
developing GDM [13, 15, 32, 35], or specific ethnic groups
(Chinese [33] or Thai [32]). Almost half of the studies used the
100 g OGTT and American Diabetes Association reference
criteria for the diagnosis of GDM [13, 14, 31, 32, 35, 38];
others used the 75 g OGTT and the International Association
of the Diabetes and Pregnancy StudyGroups reference criteria
[15, 36], or small variations of them [12, 37], or the 1999
WHO criteria [29, 34].
Quality assessment ESM Fig. 1 outlines the methodological
quality of the selected studies assessed by the QUADAS-2
tool. The majority of the studies were ranked as high quality
for most of the domains.
Meta-analysis We present data from 11 studies with extract-
able data incorporating 2,865 women of whom 794 were di-
agnosed with GDM by OGTT following adiponectin testing.
Figure 2 shows the study-specific and summary DOR for
serum adiponectin predictingGDM later in the index pregnan-
cy among women undergoing adiponectin testing prior to
OGTT. The pooled DOR was 6.4 (95% CI 4.1, 9.9). After
adjustment for age, the summary DOR did not change sub-
stantially (6.4 [95% CI 4.2, 9.8]). After adjustment for differ-
ent diagnostic criteria of GDM, the pooledDORwas 6.3 (95%
CI 3.3, 12.0). After adjustment for BMI the summary DOR
was 6.4 (95% CI 4.2, 9.8).
Figure 3 summarises the pooled sensitivity and specificity
as a summary ROC. The pooled sensitivity of predicting
GDM with the means of circulating adiponectin was 64.7%
(95%CI 51.0%, 76.4%) and the pooled specificity was 77.8%
(95% CI 66.4%, 86.1%). For diagnosis of GDM, the positive
likelihood ratio of adiponectin testing was 2.9 (95% CI 2.1,
4.1) and the negative likelihood ratio was 0.45 (95% CI 0.34,
0.61). The AUC of the ROC was 0.78 (95% CI 0.74, 0.81).
ESM Table 2 shows the corresponding negative and positive
predictive values for different prevalence points of GDM. For
a prevalence of 10% the corresponding negative predictive
value is 95.2% and the corresponding positive predictive val-
ue is 24.5%.
Sensitivity analysis The majority of the pooled studies mea-
sured circulating adiponectin during the first trimester, with
the exception of the study by Weerakiet et al [32], which
measured serum adiponectin between 21 and 27 weeks; the
study by Hedderson et al [38], which refers to pre-pregnancy
circulating levels of adiponectin; and the study by Maitland
et al [15], which measured adiponectin at 15+0–17+6 weeks’
gestation. Sensitivity analysis of the remaining studies that
assessed the value of adiponectin in the first trimester resulted
in a sensitivity of 60.3% (95%CI 46.0%, 73.1%), a specificity
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of 81.3% (95% CI 71.6%, 88.3%) and a DOR of 6.6 (95% CI
3.6, 12.1). The AUCwas 0.79 (95%CI 0.75, 0.82), which was
not substantially different from the summary estimates that
included all 11 studies, but with greater CI because of the
smaller sample size.
Three studies included patients at high risk (based on BMI,
previous history of GDM, family history of diabetes) of devel-
oping GDM [13, 15, 32]. Sensitivity analysis of the studies that
assessed the predictive accuracy of circulating adiponectin in
non-high-risk patients resulted in a sensitivity of 59.7% (95%
CI 45.7%, 72.2%), a specificity of 82.5% (95% CI 73.5%,
88.9%) and a DOR of 7.0 (95% CI 4.1, 11.8). The AUC was
0.79 (95% CI 0.76, 0.83). The summary DOR of circulating
adiponectin for patients at high risk of developing GDM [13,
15, 32] was 5.0 (95% CI 2.2, 11.3). The hierarchical model for
estimating summary sensitivity and specificity could not be
computed because of the small number of studies.
Sources of heterogeneity The estimated I2 value was 70.8%.
Univariate meta-regression analysis showed that different age
of women among the studies explained 57.9% of the hetero-
geneity. Ethnicity distribution within the studies accounted for
59.4% of between-study heterogeneity. Multivariate meta-
regression demonstrated that both covariates (ethnicity and
age) accounted for 100% of between-study heterogeneity.
The different methods of measuring adiponectin accounted
for 5.4% of the between-study variation in the DOR, yet there
was no suggestion of individual test superiority (p=0.28).
Between-study differences in the BMI, the threshold of
adiponectin for discriminating women with GDM from
women without GDM, the reference criteria of OGTT for
diagnosing GDM, the timing of the adiponectin test or the
study design had a negative r2, which suggests that each co-
variate explained less of the heterogeneity than would be ex-
pected by chance. The funnel plot shown in ESM Fig. 2 visu-
ally goes against clear evidence of bias by small sample size
(p=0.77).
Discussion
Our study suggests that early pregnancy measurement of cir-
culating adiponectin in isolation has a moderate predictive
accuracy for the development of GDM and could facilitate
targeted OGTT screening [39]. This would be particularly
relevant to areas where universal screening for GDM is not
implemented, as circulating adiponectin could be measured
inexpensively in the routine non-fasting first trimester bloods,
and should improve discrimination of those who will require
OGTT in the second trimester from those who will not. Hence,
adiponectin testing has the potential to minimise the number
of negative resource-intense OGTTs and increase the accuracy
of the risk factor approach for GDM screening, eliminating the
number and health implications of false-negative cases. In
addition, early pregnancy adiponectin may facilitate stratified
care, ensuring early identification of women at high risk of
GDM, targeted early interventions and prevention of overt
GDM development.
This is the first study assessing the summary predictive
value of low circulating adiponectin predating the diagnosis
of GDM. Low adiponectin has been linked with type 2 diabe-
tes: a 1−log μg/ml increase in serum adiponectin was associ-
ated with a 38% decrease in the risk of developing type 2
diabetes [40]. Circulating adiponectin has been extensively
studied in GDM in over 20 studies [10]. A recent meta-
analysis demonstrated that patients with GDM have substan-
tially decreased adiponectin levels compared with those with-
out GDM [11]. However, we are unaware of any study
assessing its summary prognostic accuracy for the early iden-
tification of women who will or will not develop GDM, a
much more meaningful question since, unlike the non-
pregnant situations where risk scoring can be easily followed
by fasting glucose or HbA1c, GDM diagnosis requires the
much more cumbersome and costly OGTT. Thus, any simple
test which can meaningfully lessen this burden has potential to
improve clinical practice.
Adiponectin is an adipocyte-derived hormone whose circulat-
ing levels are closely and inversely related to insulin concentra-
tion and insulin resistance, and is a good reflection of whole body
insulin sensitivity [41]. It is also inversely associated with BMI,
intra-abdominal fat, atherogenic lipid profile, hyperglycaemia,
insulin resistance and type 2 diabetes in non-pregnant women
[42].While there is debate about the direction of causality in these
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relationships, adiponectin has undoubted utility in defining more
or less insulin-resistant groups, consistent with evidence that
prognostic factors are not required to be causally associated with
the outcome of interest. We postulate that women who are more
insulin resistant and hence have a concomitant low level of
adiponectin (due to hyperinsulinaemia) outside pregnancy be-
come more insulin resistant in pregnancy and are more likely to
developGDM. That lower levels of adiponectin outside pregnan-
cy are associated with a higher risk of GDM in a subsequent
pregnancy [38] supports this hypothesis and renders adiponectin
a biological plausible prognostic factor for GDM. That the AUC
of adiponectin for GDM of 0.78 (95% CI 0.74, 0.81), and 0.79
(95% CI 0.75, 0.83) if it is measured exclusively in the first
trimester, exceeds the performance of adiposity measures for pre-
diction of type 2 diabetes (AUCs for single adiposity measures
0.66–0.73), and is equivalent to the AUCs for glycaemia vari-
ables including fasting glucose (AUCs 0.73–0.78), suggests that
it could be used in a similar fashion to these for stratification of
risk. Furthermore, adiponectin has the additional substantial ad-
vantage of being measurable in non-fasting samples [43].
Notably, combinations of multiple conventional risk fac-
tors in early pregnancy (ethnicity, BMI, family history of dia-
betes, obstetric history) often do not predict later GDM well.
A Health Technology Assessment systematic review found
that risk factors as a screening test produced sensitivities of
50–69% and specificities of 58–68% [7]. Measures of
glycaemia in early pregnancy also performed relatively poor-
ly: for example, fasting glucose has previously been shown to
have an AUC of 0.62, with a sensitivity of 47% and a speci-
ficity of 77% [44]; HbA1c has a sensitivity of 19% and a
specificity of 95%; and fructosamine has a sensitivity of
12% and a specificity of 95% [9]. In that context, the current
data suggest that adiponectin is a reasonably good predictor,
even after adjustment for BMI and age. It would appear very
important to further investigate the role of adiponectin in early
pregnancy as a clinical tool. First trimester circulating
adiponectin has the potential to improve the discrimination
between ‘high’ and ‘low’ risk women for developing GDM,
and facilitate targeted screening for GDM. Furthermore,
adiponectin performs well in women who are deemed ‘low
risk’ based on conventional risk factors (DOR 7.0 vs 5.0 in
‘high risk’) and may improve reclassification. Given the dis-
crepancy in the prevalence of GDM within the different pop-
ulations studied, the performance of adiponectin in women at
‘high risk’ and women at ‘low risk’ should be validated in
prospective cohort studies.
Strengths and weaknesses of the study This is the first study
presenting pooled data in a large number of women to assess
the predictive value of circulating adiponectin in early identifi-
cation of women who subsequently develop GDM. The
strengths of this review lie in its methodology. We used an
extensive search strategy [24], did not use a language
restriction, contacted the authors when data were not extract-
able, and used robust statistical analysis in line with established
guidance for diagnostic tests [45, 46]. Although, the process of
systematic review andmeta-analysis is a robust way of estimat-
ing the true effect size, with less random error because of in-
creased sample size, the inferences estimated by the pooled
data are subject to the limitations of the primary studies.
Between-study heterogeneity may be self-limiting in pooling
studies together to estimate a summary measure. In the current
meta-analysis, heterogeneity appeared to be mainly attributable
to the variation in age and ethnic distribution across different
studies, but the degree of heterogeneity (I2 was 70.8%, suggest-
ing a moderate degree of heterogeneity [25]) and the consisten-
cy in the direction of effect rendered it acceptable to pool stud-
ies together. We used optimal methodology to tackle the limi-
tation of heterogeneity in the meta-analysis, since the hierarchi-
cal summary ROC (HSROC) analysis takes into account the
full range of variation in the data differentiating within study
from between study and systematic from random variability
[47]. In addition, we conducted a meta-regression analysis to
investigate the sources of heterogeneity among the results of
each study and used random effects analysis, rather than fixed
effect, which incorporates unexplained heterogeneity among
studies [24]. Our systematic review included 13 studies of gen-
erally high quality. Although two studies did not have extract-
able or available data, even after contacting the authors [33,
35], we do not expect that this will have introduced substantial
bias in our pooled estimates, since they were relatively small
studies (n=42 [33] and n=32 [35]) and both showed a signif-
icant association between low adiponectin and GDM; hence,
we anticipate that their point estimates would have been in the
same direction with our pooled estimate. In addition, a propor-
tion of the patients of the study by Iannielo et al [35] had been
included in a previous study [13] which was part of our meta-
analysis. We acknowledge that the summary sensitivity and
specificity need to be interpreted and quoted with caution, as
individual studies did not have identical thresholds of
adiponectin to discriminate between those at high and those
at low risk of GDM, and summary estimates of sensitivity
and specificity can vary according to the threshold used.
However, we confirmed that the different cut-off points of
adiponectin did not attribute to the between-study heterogene-
ity in the point estimates. We also quoted the summary DORs
in each analysis, which is generally constant regardless of the
diagnostic thresholds used [48]. Our study did not suggest a
summary threshold of adiponectin, as this would be inappro-
priate given the different patients’ characteristics, including
ethnic distribution, and the variation in the methods of measur-
ing serum adiponectin. We acknowledge that the majority of
the studies included individuals from different ethnic back-
grounds: given the different thresholds of obesity within differ-
ent ethnic groups and the lack of ethnic stratification in BMI
within each study, adjustment of the summary estimates for
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BMI may not have accounted for the magnitude of the ethnic
variation in BMI. An additional limitation of our meta-analysis
is that the majority of the pooled studies were of case–control
design, which can potentially inflate the point estimate when
pooled together [49]. However, most were derived from retro-
spective analyses of cohort studies but used a case–control
approach to minimise the number of patients without GDM
and, thereby, the cost of adiponectin testing. We would antici-
pate that wider appreciation of the clinical utility of adiponectin
testing and the availability of an automated assay with equiva-
lent performance to current manually intensive ELISAs [50]
may enable universal standardised values of adiponectin and
decrease the cost of the test, especially as adiponectin can be
measured in the same non-fasting samples as routine booking
bloods. Given the current existing data sources and the lack of
individual participant data, a direct comparison between the
predictive accuracy of circulating adiponectin and other bio-
markers or a combination of circulating adiponectin with other
biomarkers or maternal characteristics was not feasible, but
should now be examined in future prospective studies.
Conclusion and implication for clinical practice and future
research First trimester biomarkers that can predict indepen-
dently or additively late pregnancy complications have the
potential to stratify women in different risk categories, initiate
different surveillance patterns and trigger preventative mea-
sures. This approach would be complementary to universal
screening for GDM at the end of the second trimester, with
diagnosis and treatment of milder types of GDM improving
perinatal outcomes. Furthermore, in many countries, includ-
ing the UK, where universal screening is not available, accu-
rate biomarkers can optimise targeted screening by reducing
the numbers of false positives and false negatives, with a po-
tential reduction in cost and the clinical implications of miss-
ing GDM cases. Current clinical guidelines suggest risk strat-
ification solely based on maternal baseline characteristics and
previous history, using a categorical approach rather than a
risk score [6]. However, the prognostic characteristics (i.e.
sensitivity and specificity) of such an approach are limited
[51]: a combination of risk stratification strategies is not asso-
ciatedwith a substantial improvement [7] and is lower than the
summary prognostic characteristics identified for serum
adiponectin. Alternative biomarkers including fasting glucose
exhibit poor prognostic characteristics [8, 9, 44].We acknowl-
edge that the moderate number of pooled studies with differ-
ent designs and characteristics limit the generalisability of our
findings, but they set the foundation for further research. We
would therefore propose that risk stratification incorporating
simple maternal characteristics, along with selected bio-
markers such as adiponectin, could improve the accuracy of
risk stratification for GDM. Confirmation of this approach in
large contemporary prospective studies, along with health
economic evaluation, is warranted in order to evaluate and
determine in conjunction with traditional risk factors the in-
cremental value of circulating adiponectin in predictingGDM.
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